BACKGROUND Leishmania is a pathogenic parasite which infects mononuclear cells in vertebrate hosts. Different strategies have been taken to develop immunity against Leishmania. DCs loaded with immunogenic antigen have resulted in different levels of Th1-type immune response and cytotoxic T lymphocytes (CTL) activity. OBJECTIVE To evaluate the potency of DCs primed with soluble Leishmania mexi...

INTRODUCTION: Leishmaniasis is endemic to the Northern, Northeastern, Central-Western, and Southeastern regions of Brazil. We aimed to assess the epidemiological situation of leishmaniasis in humans and dogs in indigenous villages located in the States of Mato Grosso and Tocantins using a serological survey conducted in May 2011. METHODS: Serum samples were collected from 470 humans and 327 ...

Sera from 35 patients suffering from Mediterranean visceral leishmaniasis (caused by Leishmania donovani infantum) and 59 patients with various forms of cutaneous leishmaniasis prevalent in the sub-Mediterranean countries (caused by Leishmania major, L. donovani infantum, or Leishmania tropica) were tested by immunoblotting and enzyme-linked immunosorbent assay (ELISA) with both membrane and so...

Visceral leishmaniasis (VL) is a zoonotic disease caused by leishmania species. Dogs are considered to be the main reservoir of VL. A number of methods and antigen-based assays are used for the diagnosis of leishmaniasis. However, currently available methods are mainly based on direct examination of tissues for the presence of parasites, which is highly invasive. A variety of serological tests ...

the aim of this study was to prepare a new formula of leishmania major (l. major) crude antigen and evaluate its effect on immune system. for this purpose l. major promastigotes were cultured, harvested, washed, and resuspended in physiologic saline and the suspensions were dispersed in five equal batches. 0.1 ml of various doses of the cocktail antigen were injected intradermaly in three group...

Background: The therapy of leishmania infection is difficult and each year 1.5 million new cases of cutaneous leishmaniasis and 500,000 new cases of visceral leishmaniasis are estimated, therefore, there is a need for an effective vaccine. Monoclonal antibody (mAb) is one of the suitable methods for isolation and purification of leishmania antigens. In this report, we produced several mAb aga...

capture elisa system was developed for diagnosis of visceral leishmaniasis (vl) using a monoclonal antibody raised against an antigen previously detected in the urine of vl patients. urine samples from confirmed vl cases from yemen, nepal, spain, sudan and brazil were tested in the capture elisa in comparison with urine samples from endemic and non-endemic areas along with urine samples from pa...

background: monoclonal antibody technology allows identification of amastigote-specific antigen in human tissue biopsies and search for a suitable vaccine candidate, which may induce a long lasting immunity.   objectives : production and partial characterization of seven monoclonal antibodies against leishmania tropica promstigotes.   methods: seven murine monoclonal antibodies of the igg isoty...

New biomarkers are needed to identify asymptomatic Leishmania infection as well as immunity following vaccination or treatment. With the aim of finding a robust biomarker to assess an effective cellular immune response, monocyte chemotactic protein 1 (MCP-1) was examined in plasma from soluble Leishmania antigen (SLA)-stimulated whole blood collected from subjects living in a Leishmania infantu...

New biomarkers are needed for monitoring the effectiveness of treatment for visceral leishmaniasis (VL). They might also improve the detection of the asymptomatic population in Leishmania-endemic areas. This paper examines the IL-2, IFN-γ, IFN-γ-induced protein 10 (IP-10), and monokine-induced-by-IFN-γ (MIG) levels in whole blood-stimulated in vitro with soluble Leishmania antigen (SLA)-taken f...